Pharmafile Logo

Peter Impey

- PMLiVE

Chase Pharmaceuticals appoints former Allergan president

Douglas Ingram joins as chief executive officer

- PMLiVE

Money-back guarantee

Why doesn’t this apply to the drugs and devices that we use?

- PMLiVE

Another lost decade for research?

What does the patent landscape look like for antibiotics, vaccines and orphan drugs?

- PMLiVE

It’s time for pharma companies to become household names

And then the sector can become meaningful to the lives of ‘ordinary’ people

- PMLiVE

Less is more: how risk-based monitoring is changing trials

A quality risk management approach is one of the biggest drivers for change in clinical research

- PMLiVE

AZ confirms interest in Acerta takeover

Possible acquisition of Netherlands-based cancer drug developer may be worth more than $5bn

- PMLiVE

NICE backs Xtandi but turns down Zytiga

Astellas and Medivation's pre-chemotherapy prostate cancer drug receives support

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa gets FDA OK

Wins accelerated US approval for non-small cell lung cancer

Centralized marketing with local market relevance: The big challenge for Pharma HQ marketers

There are good reasons for wanting to centralize and control marketing content: it reduces duplication of work, saves money and time, and also ensures a consistent level of quality. With...

Anthill Agency

- PMLiVE

Communicating the prevention message by Tam Fry

Tam Fry, spokesperson of the National Obesity Forum, discusses how prevention is key to tackling the childhood obesity epidemic in the UK.

Say Communications

- PMLiVE

Barry Labinger joins Biothera Pharmaceutical

Brings experience from Human Genome Sciences and 3M Pharmaceuticals

EU flag

Public-private partnerships ‘making a difference’ in Europe

One of those is the IMI, which has helped drug development bottlenecks

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links